Thank you, Chair.
Thank you, Dr. Douglas and Dr. Suter, for being here today. It means a great deal to us to have you both here. You have significant experience that I think is making us very aware that we do need to pursue this further.
On that, the surgeon general's report on mefloquine in conclusion number seven stated, “We did not identify any evidence (that met our inclusion criteria) addressing potential long term adverse effects of mefloquine”; yet in contrast, in 2014 the European Medicines Agency concluded, “There is enough evidence...supporting a causal relationship between mefloquine and the occurrence of long lasting and even persistent neuropsychiatric side effects.”
This to me just shows the need for more research. How do each of you reconcile two such very different reports being presented to us?